Chung Seung Min
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu 42415, Korea.
J Clin Med. 2022 May 20;11(10):2899. doi: 10.3390/jcm11102899.
This study explored the long-term effects of cadmium (Cd) exposure on osteoporosis incidence and bone mineral density (BMD). This retrospective cohort study included men aged ≥50 years and post-menopausal women from the 2001−2002 Korea Genome and Epidemiology Study. Participants previously diagnosed with osteoporosis were excluded. Blood Cd concentrations were measured and categorized as <0.5, 0.5−1.0, and >1.0 μg/L. BMD was measured using quantitative ultrasound. Osteoporosis was diagnosed when the T-score was ≤−2.5. Confounders that affect exposure and outcome were controlled. Osteoporosis incidence and differences in BMD (ΔBMD) were assessed until 2012. The osteoporosis incidence among 243 participants who were followed up for an average of 6.3 years was 22.2%. In all the participants, a dose−response relationship was observed between blood Cd and incident osteoporosis and ΔBMD (both p-for-trend < 0.01). After adjusting for age, sex, smoking, physical activity, body mass index, creatinine, and baseline BMD, a blood Cd concentration of >1.0 μg/L was an independent risk factor for incident osteoporosis and decrements in ΔBMD. In women, blood Cd concentrations of >0.5 μg/L increased the risk for osteoporosis. Exposure to Cd prospectively increases the risk for osteoporosis and decrements of ΔBMD, particularly in women, even in lower doses of Cd.
本研究探讨了镉(Cd)暴露对骨质疏松症发病率和骨密度(BMD)的长期影响。这项回顾性队列研究纳入了2001 - 2002年韩国基因组与流行病学研究中年龄≥50岁的男性和绝经后女性。先前被诊断为骨质疏松症的参与者被排除在外。测量血镉浓度并将其分为<0.5、0.5 - 1.0和>1.0 μg/L。使用定量超声测量骨密度。当T值≤ - 2.5时诊断为骨质疏松症。对影响暴露和结局的混杂因素进行了控制。评估至2012年的骨质疏松症发病率和骨密度差异(ΔBMD)。平均随访6.3年的243名参与者中骨质疏松症发病率为22.2%。在所有参与者中,观察到血镉与新发骨质疏松症和ΔBMD之间存在剂量 - 反应关系(趋势p值均<0.01)。在调整年龄、性别、吸烟、身体活动、体重指数、肌酐和基线骨密度后,血镉浓度>1.0 μg/L是新发骨质疏松症和ΔBMD降低的独立危险因素。在女性中,血镉浓度>0.5 μg/L会增加患骨质疏松症的风险。镉暴露会前瞻性地增加患骨质疏松症的风险和ΔBMD的降低,尤其是在女性中,即使是低剂量的镉也是如此。